Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (201-210 of 352) with videos related to

Pageof 36
Sort By:
United European Gastroenterology Journal|May 13, 2022
Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysisAilsa Hart, Geert D'Haens, Mareike Bereswill, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative ColitisJean-Frederic Colombel, Mark T Osterman, Andrew J Thorpe, et al.
Journal of Crohn'S & Colitis|February 28, 2019
Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional TherapyJulián Panés, James O Lindsay, Niels Teich, et al.
Wiener Klinische Wochenschrift|May 21, 2025
No increase of biopsy rates despite high rates of probable eosinophilic esophagitis in patients with esophageal food impactionLukas Neumann, Rafael Brader, Lili Kazemi-Shirazi, et al.
The Journal of Antimicrobial Chemotherapy|September 28, 2018
Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE)Christoph Högenauer, Yashwant Mahida, Andreas Stallmach, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2019
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 22, 2023
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 TrialFernando Magro, Marijana Protic, Gert De Hertogh, et al.
Therapeutic Advances in Gastroenterology|May 26, 2021
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitisDavid T Rubin, Walter Reinisch, Thomas Greuter, et al.
Journal of Hepatology|June 21, 2005
A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanineJulia Seiderer, Christoph J Zech, Walter Reinisch, et al.
The American Journal of Gastroenterology|June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid RegistryGeert DʼHaens, Walter Reinisch, Remo Panaccione, et al.
Pageof 36

Showing results (201-210 of 352) with videos related to

Sort By:
Pageof 36
United European Gastroenterology Journal|May 13, 2022
Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysisAilsa Hart, Geert D'Haens, Mareike Bereswill, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative ColitisJean-Frederic Colombel, Mark T Osterman, Andrew J Thorpe, et al.
Journal of Crohn'S & Colitis|February 28, 2019
Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional TherapyJulián Panés, James O Lindsay, Niels Teich, et al.
Wiener Klinische Wochenschrift|May 21, 2025
No increase of biopsy rates despite high rates of probable eosinophilic esophagitis in patients with esophageal food impactionLukas Neumann, Rafael Brader, Lili Kazemi-Shirazi, et al.
The Journal of Antimicrobial Chemotherapy|September 28, 2018
Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE)Christoph Högenauer, Yashwant Mahida, Andreas Stallmach, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2019
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeWilliam J Sandborn, Julian Panés, Bruce E Sands, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 22, 2023
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 TrialFernando Magro, Marijana Protic, Gert De Hertogh, et al.
Therapeutic Advances in Gastroenterology|May 26, 2021
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitisDavid T Rubin, Walter Reinisch, Thomas Greuter, et al.
Journal of Hepatology|June 21, 2005
A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanineJulia Seiderer, Christoph J Zech, Walter Reinisch, et al.
The American Journal of Gastroenterology|June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid RegistryGeert DʼHaens, Walter Reinisch, Remo Panaccione, et al.
Pageof 36